Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Description

The global Biologics Safety Testing Market is projected to be worth USD 8.56 billion by 2030.

According to SPER Market Research, the Biologics Safety Testing Market is estimated to reach USD 8.56 billion by 2030 with a CAGR of 10.8%.

The expansion of the biologics and biosimilars markets, increasing concerns over cell culture contamination, and rising biopharmaceuticals research & development activities and investments, emerging markets, and growing biopharmaceutical outsourcing; are the key driver for the escalation of the market.

Impact of COVID-19 on the Biologics Safety Testing Market

To provide biologics safety testing for developing safety test kits, manufacturing of vaccines testing to treat and target the infection. Pharmaceutical and biopharmaceutical companies and the biologics safety testing market have taken steps toward research in biologics safety testing.

Scope of the report:

Market size available for years: 2019-2030
Base year considered: 2021
Forecast period: 2022-2030

Segments covered By Product, By Application, By End-User, By Region.

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa.

Companies Covered:

Agilent Technologies, Inc., Almac Group, Associates of Cape Cod, Inc. BioMerieux SA, Bio-Rad Laboratories, Inc., Charles River Laboratories, Inc., Lonza, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fujifilm Wako Pure Chemical Corporation, Maravai Lifesciences, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories, LLC, Pacific BioLabs, PromoCell GmbH, Sartorius AG, SGS SA, Thermo Fisher Scientific, Inc., WuXi AppTec.

Driver: expansion in the biosimilars and biologics markets

Heavy investments in the development of biologics and biosimilars by big companies. Growth in the biosimilars and biologics markets, Growing concerns over cell culture contamination, rising biopharmaceuticals R&D activities and investments; are the key factors, which drive the market expansion.

Opportunity: Emerging markets offer profitable opportunities

Emerging markets offer rewarding opportunities, and growing biopharmaceutical outsourcing; will provide enormous opportunities in the Biologics Safety Testing Market.

Challenges: lack of skilled professionals

Lack of skilled personnel to handle the advanced technologies and the development of new and improved safety testing.

Global Biologics Safety Testing Market, By Product & Service:

Based on the Product & Service, Global Biologics Safety Testing Market is segmented as; Consumables, Instrument, and Services.

Global Biologics Safety Testing Market, By Application:

Based on the Application, Global Biologics Safety Testing Market is segmented as; Blood and Blood Products Manufacturing, Cellular & Gene Therapy Products Manufacturing, Monoclonal Antibodies Manufacturing, and Vaccine Manufacturing.

Global Biologics Safety Testing Market, By Test Type:

Based on the Test Type, Global Biologics Safety Testing Market is segmented into; Bioburden Tests, Endotoxin tests, Mycoplasma Tests, Residual Host-cell Proteins & DNA Detection Tests, Sterility tests, and Virus safety tests.

Global Biologics Safety Testing Market, By Region:

North America dominates the biggest share of the market; this is due to the increasing academic and government investments, quick expansion in the biopharmaceutical industry, growing demand for high-quality research tools for data reproducibility, and growing alertness among consumers about product safety.

Product Code: BIOT2222

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Biologics Safety Testing Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Biologics Safety Testing Market, By Product & Service, 2019-2030 (USD Million)

6.1. Consumables
6.2. Instrument
6.3. Services

7. Global Biologics Safety Testing Market, By Application, 2019-2030 (USD Million)

7.1. Blood and Blood Products Manufacturing
7.2. Cellular & Gene Therapy Products Manufacturing
7.3. Monoclonal Antibodies Manufacturing
7.4. Other Application
7.5. Vaccine Manufacturing

8. Global Biologics Safety Testing Market, By Test Type , 2019-2030 (USD Million)

8.1. Bioburden Tests
8.2. Endotoxin Test
8.3. Mycoplasma Tests
8.4. Residual Host-cell Proteins & DNA Detection Tests
8.5. Sterility Test
8.6. Virus safety Test

9. Global Biologics Safety Testing Market, By Region, 2019-2030 (USD Million)

9.1. North America
- 9.1.1. United States
- 9.1.2. Canada
- 9.1.3. Mexico
9.2. Europe
- 9.2.1. Germany
- 9.2.2. United Kingdom
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
9.4. South America
- 9.4.1. Brazil
- 9.4.2. Argentina
- 9.4.3. Rest of South America
9.5. Middle East & Africa
- 9.5.1. Kingdom of Saudi Arabia
- 9.5.2. United Arab Emirates
- 9.5.3. Rest of Middle East & Africa

10. Company Profiles

10.1. Agilent Technologies, Inc.
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
10.2. Almac Group
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
10.3. Associates of Cape Cod, Inc.
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
10.4. BioMerieux SA
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
10.5. Bio-Rad Laboratories, Inc.
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
10.6. Charles River Laboratories, Inc. Lonza
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
10.7. Eurofins Scientific
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
10.8. F. Hoffmann-La Roche Ltd.
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
10.9. Fujifilm Wako Pure Chemical Corporation
- 10.9.1. Company details
- 10.9.2. Financial outlook
- 10.9.3. Product summary
- 10.9.4. Recent developments
10.10. Maravai Lifesciences
- 10.10.1. Company details
- 10.10.2. Financial outlook
- 10.10.3. Product summary
- 10.10.4. Recent developments
10.11. Merck KGaA
- 10.11.1. Company details
- 10.11.2. Financial outlook
- 10.11.3. Product summary
- 10.11.4. Recent developments
10.12. Microcoat Biotechnologie GmbH
- 10.12.1. Company details
- 10.12.2. Financial outlook
- 10.12.3. Product summary
- 10.12.4. Recent developments
10.13. Nelson Laboratories, LLC
- 10.13.1. Company details
- 10.13.2. Financial outlook
- 10.13.3. Product summary
- 10.13.4. Recent developments
10.14. Pacific BioLabs
- 10.14.1. Company details
- 10.14.2. Financial outlook
- 10.14.3. Product summary
- 10.14.4. Recent developments
10.15. PromoCell GmbH
- 10.15.1. Company details
- 10.15.2. Financial outlook
- 10.15.3. Product summary
- 10.15.4. Recent developments
10.16. QIAGEN
- 10.16.1. Company details
- 10.16.2. Financial outlook
- 10.16.3. Product summary
- 10.16.4. Recent developments
10.17. Sartorius AG
- 10.17.1. Company details
- 10.17.2. Financial outlook
- 10.17.3. Product summary
- 10.17.4. Recent developments
10.18. SGS SA
- 10.18.1. Company details
- 10.18.2. Financial outlook
- 10.18.3. Product summary
- 10.18.4. Recent developments
10.19. Thermo Fisher Scientific, Inc.
- 10.19.1. Company details
- 10.19.2. Financial outlook
- 10.19.3. Product summary
- 10.19.4. Recent developments
10.20. WuXi AppTec
- 10.21.1. Company details
- 10.21.2. Financial outlook
- 10.21.3. Product summary
- 10.21.4. Recent developments